Dapagliflozin Gets Expanded Heart Failure Indication in Europe

The European Commission has expanded the indication of the SGLT2 inhibitor to include HF with mildly reduced and preserved ejection fraction, based on the DELIVER phase 3 trial.

Related Keywords

Boston ,Massachusetts ,United States , ,Astrazeneca ,European Society Of Cardiology ,European Commission ,Drug Administration ,Harvard Medical School ,Medicinal Products ,Human Use ,European Medicines Agency ,New England Journal ,European Society ,Heart Failure ,Sglt2 Inhibitors ,Odium Glucose Transporter 2 Inhibitors ,Odium Glucose Co Transporter 2 Inhibitors ,Sodium Glucose Cotransporter 2 Inhibitors ,Ejection Fraction Ef ,Eft Ventricular Ejection Fraction Lvef ,Heart ,Diabetes Mellitus Type 2 ,Iabetes Mellitus Type Ii ,Type 2 Diabetes ,Europe ,European ,Clinical Research ,Clinical Trials ,Linical Studies ,Medical Literature ,Books ,Sex ,